EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors

Roberta Scafetta, Raffaella Troiano, Alessandra Guarino, Carla Gullotta, Cristina Fiore, Luisana Sisca, Elena Speziale, Arianna Travisani, Fernando Zannino, Giovanni Miraglia, Marco Donato, Simone Foderaro und 48 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.117019 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Roberta Scafetta und 59 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Medicine and …. Hauptthemen laut MEDLINE: Breast Neoplasms, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Bone-only HR+/HER2 - metastatic breast cancer generally has a favourable prognosis, but some patients develop visceral metastases. We aimed to quantify visceral conversion and identify reproducible baseline correlates during CDK4/6 inhibitor (CDK4/6i) therapy. METHODS: This multicentre retrospective cohort included 692 patients treated with palbociclib, ribociclib, or abemaciclib plus endocrine therapy as first- or second-line treatment across 24 Italian centres. Visceral conversion was analysed in a competing-risks framework, with skeletal progression or death without prior visceral conversion as competing events. Eighteen baseline candidate predictors derived from a 35-variable dataset were evaluated using Fine-Gray modelling, ridge penalisation, bootstrap stability assessment, and cause-specific Cox sensitivity analyses. RESULTS: Over a median follow-up of 31 months, 162 patients (23.4%) developed visceral conversion after a median of 17.0 months. Cumulative incidence was 8.8%, 17.5%, and 24.5% at 12, 24, and 36 months, respectively; median overall survival after visceral conversion was 18.0 months. Progesterone receptor (PR) expression was the most stable tumour-biological correlate, with complete sign concordance and a median absolute coefficient rank of 1 across 500 bootstrap resamples. In the mutually adjusted Fine-Gray model, higher PR expression was associated with lower visceral-conversion risk (sHR per 10-percentage-point increase, 0.929; 95% CI, 0.889-0.971; p = 0.0012), with consistent direction across complementary analyses. However, stand-alone PR prediction remained modest (24-month IPCW AUC, 0.585; Brier score, 0.142; IPA, 1.1%; O:E, 1.00), limiting individual-level clinical utility. CONCLUSIONS: Broad baseline-variable profiling identified PR expression as the most reproducible tumour-biological correlate of visceral conversion, although its stand-alone predictive performance was modest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProtein Kinase InhibitorsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Bone NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesErb-b2 Receptor Tyrosine KinasesMiddle AgedReceptors, ProgesteroneAgedPiperazinesReceptors, EstrogenPyridinesAdultBenzimidazolesPurinesAminopyridinesViscera

Stichwörter der Autor:innen

Bone-only metastasesCDK4/6 inhibitorsCompeting risksHormone receptor-positive breast cancerProgesterone receptorVisceral conversion

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneProtein Kinase InhibitorsCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4PiperazinespalbociclibReceptors, EstrogenPyridinesCDK4 protein, human

Autor:innen und Institutionen

  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo…
  • Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy.
  • Medical Oncology Unit, Santa Rosa Hospital, Department of Oncology and Hematology, Strada Sammartinese snc, Viterbo 01100, Italy.
  • Division of Medical Oncology, "G. Martino" University Hospital, Via Consolare Valeria 1, Messina 98124, Italy.
  • Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, Rome 00128, Italy.
  • Hospital Pharmacy Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy.

Zitieren

APA

Scafetta, R., Troiano, R., Guarino, A., Gullotta, C., Fiore, C., Sisca, L., Speziale, E., Travisani, A., Zannino, F., Miraglia, G., Donato, M., Foderaro, S., Venuti, F., Vilardi, F. A., Ricozzi, V., Iuliani, M., Simonetti, S., Cavaliere, S., Cortellini, A., …, & Caffo, O. (2026). Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117019

Vancouver

Scafetta R, Troiano R, Guarino A, Gullotta C, Fiore C, Sisca L, et al. Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117019

BibTeX
@article{Scafetta2026,
  author = {Scafetta, Roberta and Troiano, Raffaella and Guarino, Alessandra and Gullotta, Carla and Fiore, Cristina and Sisca, Luisana and Speziale, Elena and Travisani, Arianna and Zannino, Fernando and Miraglia, Giovanni and Donato, Marco and Foderaro, Simone and Venuti, Fabio and Vilardi, Francesco Antonio and Ricozzi, Valentina and Iuliani, Michele and Simonetti, Sonia and Cavaliere, Silvia and Cortellini, Alessio and La Cesa, Annalisa and Di Mattia, Andrea and Lombardo, Michela and Angelone, Martina and Botticelli, Andrea and Scagnoli, Simone and Pisegna, Simona and Criscitiello, Carmen and Pedersini, Rebecca and Sposetti, Caterina and Tiberi, Elisa and D'Auria, Giuliana and Vergati, Matteo and Mazzotta, Marco and Caputo, Roberta and Verrazzo, Annarita and Rossino, Maria Grazia and Garrone, Ornella and Domati, Federica and Piombino, Claudia and Gatti, Federica and Filomeno, Lorena and Arcuri, Teresa and Puce, Federica and Riva, Federica and Palleschi, Michela and Sirico, Marianna and Piras, Marta and Stucci, Luigia Stefania and De Lisi, Delia and Orsaria, Paolo and Grasso, Antonella and Ippolito, Edy and Ramella, Sara and Visani, Luca and Livi, Lorenzo and Gori, Stefania and Rossi, Luigi and Meattini, Icro and Tagliaferri, Barbara and Caffo, Orazio},
  title = {Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.117019}
}
Kostenlos starten →